© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Tomasz M. Beer, MD | Authors
Articles
Building on Last Year’s Advances
July 15, 2015
The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
June 15, 2015
Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.
Targeted Therapy in Prostate Cancer: Is There Hope Beyond the Androgen Receptor?
July 15, 2013
We need to understand each patient’s cancer and its microenvironment well enough to develop targeted treatments that will kill the tumor the first time-for if we let it escape, 70 years of prostate cancer research teaches us that our job will only get harder.
Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies
April 27, 2012
Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.